Our Foundation's goal to further advance the science of xenotransplantation is best optimized through the establishment of two separate but affiliated organizations. Our business model harnesses the vision, creativity, and mission-driven passion of the non-profit sector (XenoTherapeutics Foundation) with the resources, pragmatism, and expertise of the for-profit corporation (XenoTherapeutics Corporation) to support the rapid development of tangible therapeutic solutions to address a critical, growing unmet medical need. 


XenoTherapeutics Foundation is focused on research and development. Its responsibilities include animal husbandry, recovery of xenotransplantation tissues and organs, and preclinical research of promising technology. XenoTherapeutics Foundation’s status as a non-profit private foundation allows us to collaborate with the academic institutions that have been instrumental in the development of our fundamental science and technology. Furthermore, the nonprofit is a better suited, more compelling candidate for many private, federal, and state grants.

Commercialization of these life-saving products is outside the scope of the nonprofit’s mission. Thus, a complementary for-profit entity, XenoTherapeutics Corporation, exclusively sub-licenses intellectual property from XenoTherapeutics Foundation for commercialization purposes. XenoTherapeutics Corporation can raise money through traditional channels open to for-profit entities (stock sales, loans, etc). It then provides XenoTherapeutics Foundation with a steady source of funding via a sponsored research agreement for continued research efforts and further development since relying on an unpredictable stream of charitable contributions is enormously disruptive to the process of funding essential research and building quality teams. Both entities continually collaborate on intellectual property strategy.